The initiation of cell division integrates a large number of intra- and extracellular inputs. D-type cyclins (hereafter, cyclin D) couple these inputs to the initiation of DNA replication1. Increased levels of cyclin D promote cell division by activating cyclin-dependent kinases 4 and 6 (hereafter, CDK4/6), which in turn phosphorylate and inactivate the retinoblastoma tumour suppressor. Accordingly, increased levels and activity of cyclin D–CDK4/6 complexes are strongly linked to unchecked cell proliferation and cancer2,3. However, the mechanisms that regulate levels of cyclin D are incompletely understood4,5. Here we show that autophagy and beclin 1 regulator 1 (AMBRA1) is the main regulator of the degradation of cyclin D. We identified AMBRA1 in a genome-wide screen to investigate the genetic basis of the response to CDK4/6 inhibition. Loss of AMBRA1 results in high levels of cyclin D in cells and in mice, which promotes proliferation and decreases sensitivity to CDK4/6 inhibition. Mechanistically, AMBRA1 mediates ubiquitylation and proteasomal degradation of cyclin D as a substrate receptor for the cullin 4 E3 ligase complex. Loss of AMBRA1 enhances the growth of lung adenocarcinoma in a mouse model, and low levels of AMBRA1 correlate with worse survival in patients with lung adenocarcinoma. Thus, AMBRA1 regulates cellular levels of cyclin D, and contributes to cancer development and the response of cancer cells to CDK4/6 inhibitors.
CDK4/6 inhibitors have been approved to treat breast cancer, and are under investigation for the treatment of many additional types of cancer6. Clinical and preclinical studies have begun to identify mechanisms of inherent or acquired resistance to these inhibitors, such as loss of the retinoblastoma tumour-suppressor protein (RB) or upregulation of cyclin E (an activator of CDK2, which can in turn phosphorylate and inactivate RB)7,8. However, many cases of resistance lack a clear molecular basis9. To address this gap in knowledge, we sought to identify genes, in an unbiased manner, whose loss affects sensitivity to the CDK4/6 inhibitor palbociclib, with the hope that this approach may help us to better understand the regulatory networks that control cell cycle progression.
AMBRA1 loss dampens response to CDK4/6 inhibitors
We performed a genome-wide CRISPR–Cas9 screen in U937 cells and identified hundreds of genes whose knockout significantly altered proliferation under palbociclib treatment, including known members of the RB pathway (Fig. 1a, Extended Data Fig. 1a–f, Supplementary Tables 1–3). We investigated AMBRA1 further because the loss of this gene had the largest protective effect. The growth advantage of U937 AMBRAl-knockout and RB1 (which encodes RB)-knockout cells upon palbociclib treatment was validated in independent clones and was associated with impaired cell cycle arrest (Fig. 1b–d, Extended Data Fig. 1g–l, Supplementary Fig. 1). A similar decreased sensitivity to CDK4/6 inhibition upon AMBRA1 knockout was observed with abemaciclib (another CDK4/6 inhibitor), as well as in four additional cancer cell lines that contain wild-type RB (Extended Data Fig. 1m–o).
Levels of cyclin D increase upon AMBRA1 loss
AMBRAl-knockout cells showed increased phosphorylation of RB and cell-cycle gene expression with palbociclib treatment compared to control cells (Fig. 1e, Extended Data Fig. 1p, q), which suggested an increased activity of cyclin-dependent kinases. Accordingly, we observed a notable increase of proteins in the cyclin-D family and a modest increase in CDK4 in all of the AMBRA1-knockout cell lines that we tested (Fig. 1f, Extended Data Fig. 2a–c). Acute knockdown of AMBRA1 using short interfering RNA (siRNA) suggested that increased levels of cyclin D are a more immediate consequence of AMBRA1 loss than are increases in CDK4 (Extended Data Fig. 2d, e). Codependency data from the Cancer Dependency Map further suggested a functional link between AMBRA1 and the RB pathway (Extended Data Fig. 2f, g, Supplementary Table 4). Our RNA-sequencing analysis of control and AMBRA1-knockout cells showed few statistically significant (P < 0.01) differences between the two genotypes (Extended Data Fig. 2h, i, Supplementary Table 5). We performed shotgun proteomics analyses, which also identified few changes upon AMBRA1 loss—however, the three D-type cyclins (cyclin D1, cyclin D2 and cyclin D3) were in the top 11 of 25 upregulated proteins (Fig. 1g, Supplementary Tables 6–8). Finally, AMBRA1 knockout also led to increased levels of cyclin D in mouse embryos (Extended Data Fig. 3a–d). Thus, AMBRA1 controls the protein levels of D-type cyclins in all of the contexts we examined (in normal and cancer cells, and in vitro and in vivo).
Cyclin D upregulation mimics AMBRA1 loss
AMBRA1 can promote autophagy10 and inhibit mTOR activity11 and MYC12, all of which could affect cell cycle progression and the response to CDK4/6 inhibition. However, we did not observe reproducible changes in these pathways upon AMBRA1 loss in U937 cells, with or without palbociclib treatment (Extended Data Fig. 4a–h). Our proteomics analysis of AMBRA1-knockout U2OS cells suggested upregulation of PLK1 and Aurora kinases (Fig. 1g), which has previously been associated with palbociclib resistance8,13, but these observations were not reproducible in independent experiments (Extended Data Fig. 4i, j). Thus, these pathways probably do not account for the decreased response to CDK4/6 inhibition of AMBRA1-mutant cells. By contrast, overexpression of the three D-type cyclins or of a phosphomutant form of cyclin D1 (cyclin D1(T286A)), which is stable and highly expressed14,15, was sufficient to promote S-phase entry and decreased sensitivity to low doses of palbociclib (Fig. 1h, i, Extended Data Fig. 5a–d). Differences in palbociclib response between overexpression of cyclin D and loss of AMBRA1 are possibly due to limitations of the ectopic expression system for cyclin D. AMBRA1-knockout cells remained highly dependent on cyclin D1 for proliferation, similar to control cells (Fig. 1j, Extended Data Fig. 5e).
These observations raised the question of how upregulation of cyclin D mediates an increased tolerance of CDK4/6 inhibitors. Compared to control cells, immunoprecipitation of cyclin D1 pulled down more CDK4 and CDK2 from AMBRA1-knockout cells or cells expressing cyclin D1(T286A), and reciprocal CDK2 immunoprecipitation confirmed the increased binding of cyclin D1 to CDK2 in both of these cell models (Fig. 1k, l). Cyclin D–CDK2 complexes can phosphorylate RB16–18, and increased activity of CDK2 promotes resistance to CDK4/6 inhibitors8,19,20. In addition, the binding of the CDK2 inhibitor p27 to CDK2 was decreased in AMBRA1-knockout cells and cells expressing cyclin D1(T286A), and at the same time p27 was more abundantly bound to cyclin D1 and CDK4 (Fig. 2k, l, Extended Data Fig. 5f). p27–cyclin D–CDK4 trimers are active and resistant to palbociclib in some contexts21,22. Thus, increased levels of cyclin D lead to changes associated with increased CDK4/6 and CDK2 activity, which suggests that upregulation of cyclin D is a key mechanism by which the loss of AMBRA1 influences cell cycle progression and the response to CDK4/6 inhibitors.
AMBRA1 regulates the ubiquitylation of cyclin D
Cyclin D typically has a short half-life, which is thought to allow for precise control of CDK4/6 activity during G1 progression and to limit levels of cyclin D in S phase, in which it is detrimental to DNA replication23. We blocked translation using cycloheximide, which revealed a marked increase in the half-life of all three D-type cyclins in AMBRA1-knockout cells (Fig. 2a, b). Acute proteasome inhibition with bortezomib—but not inhibition of autophagy—was sufficient to increase the levels of cyclin D in wild-type cells, whereas proteasome inhibition did not further increase the levels of cyclin D in AMBRA1-knockout cells (Fig. 2c, d, Extended Data Fig. 6a–c). Cyclin D1 phosphorylation at T286, which precedes cyclin D1 ubiquitylation and degradation14,15, was increased in AMBRA1-knockout cells to levels similar to those in wild-type cells treated with bortezomib (Fig. 2c, e). AMBRA1-knockout cells or cells in which AMBRA1 was knocked down showed lower levels of cyclin D1 polyubiquitylation compared to control cells (Fig. 2f–h, Extended Data Fig. 6d–h, Supplementary Table 9). Mass spectometry analysis of immunoprecipitated ubiquitylated proteins showed reduced cyclin D1 ubiquitylation at several lysine residues upon knockdown of AMBRA1 (Fig. 2i, j, Extended Data Fig. 6i–k, Supplementary Table 10). Thus, AMBRA1 promotes ubiquitylation and proteasomal degradation of cyclin D.
CRL4AMBRA1 directly ubiquitylates cyclin D
Our immunoprecipitation of cyclin D with AMBRA1 upon proteasome inhibition (to stabilize cyclin D) suggested that AMBRA1 may directly regulate cyclin D ubiquitylation (Fig. 2k, Extended Data Fig. 7a). AMBRA1 belongs to the DDB1 and CUL4-associated factor family of proteins, which specifies substrates for CUL4–RING E3 ubiquitin ligase (CRL4) complexes24,25. Inhibition of all cullin-RING ligase complexes with the neddylation inhibitor MLN4924 increased levels of cyclin D1 in control cells but not in AMBRA1-knockout cells, whereas MYC (another target of cullin-RING ligases) accumulated regardless of AMBRA1 status (Fig. 3a, b). We found a predominant association of AMBRA1 with CUL4A and CUL4B, consistent with previous studies11,24, but only CUL4B knockdown led to increased levels of cyclin D1 and blocked cyclin D1 polyubiquitylation upon AMBRA1 overexpression (Fig. 3c–e, Extended Data Fig. 7b, c). A mutant AMBRA1 that cannot bind CRL4 (AMBRA1(ΔH))24 could not rescue increased levels of cyclin D1 in AMBRA1-knockout cells nor increase cyclin D1 polyubiquitylation (Fig. 3f, g, Extended Data Fig. 7d–f). AMBRA1 knockdown did not further increase the half-life of cyclin D1(T286A), and this cyclin D1 phosphomutant showed decreased binding to AMBRA1 (Extended Data Fig. 7g–i). Finally, in in vitro ubiquitylation assays, high-molecular-weight polyubiquitylated cyclin D1 species accumulated in a time-dependent manner and required the presence of both CRL4AMBRA1 and recombinant E1 and E2 proteins (Fig. 3h, i, Extended Data Fig. 8a–c). Altogether, these data show that CRL4AMBRA1 ubiquitylates Cyclin D.
AMBRA1 loss promotes lung adenocarcinoma
Mutations in AMBRA1 are found in 2% of the ‘Pan-Cancer Atlas’ studies of The Cancer Genome Atlas (TCGA), and two cancer-derived mutations in AMBRA1 impaired its ability to control the levels of cyclin D (Extended Data Fig. 9a–c), which suggests that AMBRA1 may act as a context-dependent tumour suppressor. We tested this idea in a mouse model of lung adenocarcinoma driven by oncogenic KRAS using Tuba-seq, a highly quantitative tumour barcoding system26. We intratracheally infected KrasLSL-G12D/+;Rosa26LSL-tdTomato;H11LSL-Cas9 (hereafter, KTC) and KrasLSL-G12D/+;Trp53fl/fl;Rosa26LSL-tdTomato;H11LSL-Cas9 (hereafter, KPTC) mice with lenti-single guide (sg)RNA–Cre pools that consisted of sgRNAs against Ambra1 and three other tumour suppressors (Rb1, Apc and Rbm10) as well as five inert sgRNAs. KrasLSL-G12D/+;Rosa26LSL-tdTomato (hereafter, KT) mice (without Cas9) were used to account for differences in sgRNA representation in the viral pool (Fig. 4a). Sequencing and tallying the integrated barcodes from tumour-bearing lungs revealed that loss of Ambra1 had the greatest effect on tumour size among all tumour suppressor genes tested in KTC and KPTC mice (Fig. 4b, Extended Data Fig. 9d–g). Loss of Ambra1 resulted in an increase in tumour burden—accompanied by increased levels of cyclin D—in independent KrasLSL-G12D/+;H11LSL-Cas9 (hereafter, KC) mice (Fig. 4c, d, Extended Data Fig. 9h,i). Similarly, AMBRA1 knockout led to increased levels of cyclin D1 and greater tumour growth in a human xenograft model of lung adenocarcinoma (Extended Data Fig. 10a–c). In the lung adenocarcinoma dataset from TCGA, lower expression of AMBRA1 mRNA was associated with worse overall survival in a Kaplan–Meier analysis of patients with KRASG12-mutant tumors (log-rank test, P=0.0017) (Fig. 4e). This association was also significant in a multivariate Cox proportional hazard model that adjusted for key clinical covariates (log hazard ratio of −0.5, 95% confidence interval of −0.92 to −0.09, P = 0.015) (Fig. 4f). Additionally, a stepwise linear regression model that included RB pathway genes (Supplementary Methods) identified a significant inverse correlation between AMBRA1 expression and protein levels of cyclin D1 (Extended Data Fig. 10d). These associations were not observed in samples that contained wild-type KRAS or mutant EGFR (Extended Data Fig. 10e–j). Thus, AMBRA1 acts as a tumour suppressor in lung adenocarcinoma driven by mutant KRAS.
Discussion
Our work, and accompanying studies27,28, conclusively identifies CRL4AMBRA1 as a major regulator of the stability of cyclin D in every context we examined and places AMBRA1 as a member of the RB pathway (Extended Data Fig. 11). Additional mechanisms may further control the stability of D-type cyclins in more specific contexts4,29. Given the various cellular functions of AMBRA1, it may serve as a central node to coordinate the cell cycle, cell growth and cell death in response to a variety of inputs. However, our data in lung adenocarcinoma suggest that the oncogenic effects of the loss of AMBRA1 may depend on the genetic context, similar to other members of the RB pathway30. Our work highlights the complexities of the factors that regulate how cancer cells respond to CDK4/6 inhibitors. Increased levels of cyclin D may promote resistance to CDK4/6 inhibitors by directly and indirectly increasing the activity of both CDK4/6 and CDK2 in cells, but upregulation of cyclin D has also previously been linked to increased sensitivity to CDK4/6 inhibition19,20,31–35. These observations underscore the need to further explore the mechanisms that regulate the levels and activity of complexes containing CDK4/6 or CDK2 in human tumours to optimize the use of CDK4/6 or CDK2 inhibitors in a broad range of patients with cancer.
Online content
Any methods, additional references, Nature Research reporting summaries, source data, extended data, supplementary information, acknowledgements, peer review information; details of author contributions and competing interests; and statements of data and code availability are available at https://doi.org/10.1038/s41586-021-03474-7.
Extended Data
Supplementary Material
Acknowledgements
We thank S. Rubin and J. Skotheim for critical reading of the manuscript; A. Koff, V. Dulic and K. Keyomarsi for helpful discussions; and all of the members of the laboratory of J.S., and especially G. Coles, for their help and support throughout this study. Research reported in this Article was supported by the NIH (J.S., R01CA228413 and 1R35CA231997; A.C.C., 1F99CA245471-01; E.E.J., 2T32CA009302; R.C., 5T32GM007276; M.M.W. and D.A.P., R01CA2344349; and N.J.K., P50AI150476 and U54CA209891), the California TRDRP (J.S., 28IR-0046) and the NSF (GRFP, to A.C.C.). E.E.J. and M.C.L. were supported by a Stanford Graduate Fellowship. S.L. was supported by a Boehringer Ingelheim Fonds MD Fellowship. C.L. is the Connie and Bob Lurie Fellow of the Damon Runyon Cancer Research Foundation (DRG-2331). J.S. is the Harriet and Mary Zelencik Scientist in Children’s Cancer and Blood Diseases and the Elaine and John Chambers Professor in Pediatric Cancer.
Competing interests J.S. has received research funding from Stemcentrx/Abbvie, Pfizer and Revolution Medicines. M.M.W. and D.P. have equity in, and are advisors for, D2GOncology. C.C. is a scientific advisor to GRAIL and reports stock options as well as consulting for GRAIL and Genentech. N.J.K. has received research support from Vir Biotechnology and F. Hoffmann-La Roche. The authors declare no other competing interests.
Footnotes
Additional information
Supplementary information The online version contains supplementary material available at https://doi.org/10.1038/s41586-021-03474-7.
Peer review information Nature thanks Marianne Bronner, Piotr Sicinski and the other, anonymous, reviewer(s) for their contribution to the peer review of this work. Peer reviewer reports are available.
Reprints and permissions information is available at http://www.nature.com/reprints.
Reporting summary
Further information on research design is available in the NatureResearch Reporting Summary linked to this paper.
Data availability
Sequencing data from Tuba-seq experiments and RNA-sequencing data from AMBRA1-knockout U2OS cells are available from the Gene Expression Omnibus under accession numbers GSE146303 and GSE159920, respectively. Mass spectrometry data from shotgun proteomics experiments and analysis of ubiquitylated proteins are available through the ProteomeXchange Consortium, with dataset identifiers PXD021789 and PXD022111, respectively. Public nonprotected RNA-sequencing, copy number alteration, exome sequencing and reverse-phase protein array lung adenocarcinoma datasets from the TCGA were downloaded from https://gdc.cancer.gov/. Clinical data were obtained from a previous publication36 (PMID: 29625055). Gene dependency data from the Cancer Dependency Map are publicly available at www.depmap.org. Protein sequences for mass spectrometry analysis were obtained from the NCBI Homo sapiens protein database (ftp://ftp.ncbi.nlm.nih.gov/ref-seq/release/release-notes/archive/RefSeq-release86.txt, downloaded 05/11/2018) (shotgun mass spectrometry) and from Uniprot (https://www.uniprot.org/uniprot/?query=proteome:UP000005640%20reviewed:yes, downloaded 02/28/2020) (ubiquitin remnant profiling). All other data are available in the Article and supplementary information, or from the corresponding author upon reasonable request. Source data are provided with this paper.
References
- 1.Deshpande A, Sicinski P & Hinds PW Cyclins and cdks in development and cancer: a perspective. Oncogene 24, 2909–2915 (2005). [DOI] [PubMed] [Google Scholar]
- 2.Sherr CJ Cancer cell cycles. Science 274, 1672–1677 (1996). [DOI] [PubMed] [Google Scholar]
- 3.Malumbres M & Barbacid M Cell cycle, CDKs and cancer: a changing paradigm. Nat. Rev. Cancer 9, 153–166 (2009). [DOI] [PubMed] [Google Scholar]
- 4.Kanie T et al. Genetic reevaluation of the role of F-box proteins in cyclin D1 degradation. Mol. Cell. Biol. 32, 590–605 (2012). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Qie S & Diehl JA Cyclin D degradation by E3 ligases in cancer progression and treatment. Semin. Cancer Biol. 67, 159–170 (2020). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Sherr CJ, Beach D & Shapiro GI Targeting CDK4 and CDK6: from discovery to therapy. Cancer Discov. 6, 353–367 (2016). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Walter DM et al. RB constrains lineage fidelity and multiple stages of tumour progression and metastasis. Nature 569, 423–427 (2019). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Wander SA et al. The Genomic landscape of intrinsic and acquired resistance to cyclin-dependent kinase 4/6 inhibitors in patients with hormone receptor-positive metastatic breast cancer. Cancer Discov. 10, 1174–1193 (2020). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Schoninger SF & Blain SW The ongoing search for biomarkers of CDK4/6 inhibitor responsiveness in breast cancer. Mol. Cancer Ther. 19, 3–12 (2020). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10.Fimia GM et al. Ambra1 regulates autophagy and development of the nervous system. Nature 447, 1121–1125 (2007). [DOI] [PubMed] [Google Scholar]
- 11.Antonioli M et al. AMBRA1 interplay with cullin E3 ubiquitin ligases regulates autophagy dynamics. Dev. Cell 31, 734–746 (2014). [DOI] [PubMed] [Google Scholar]
- 12.Cianfanelli V et al. AMBRA1 links autophagy to cell proliferation and tumorigenesis by promoting c-Myc dephosphorylation and degradation. Nat. Cell Biol. 17, 706 (2015). [DOI] [PubMed] [Google Scholar]
- 13.Montaudon E et al. PLK1 inhibition exhibits strong anti-tumoral activity in CCND1-driven breast cancer metastases with acquired palbociclib resistance. Nat. Commun. 11, 4053 (2020). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14.Alt JR, Cleveland JL, Hannink M & Diehl JA Phosphorylation-dependent regulation of cyclin D1 nuclear export and cyclin D1-dependent cellular transformation. Genes Dev. 14, 3102–3114 (2000). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15.Lin DI et al. Phosphorylation-dependent ubiquitination of cyclin D1 by the SCFFBX4-aB crystallin complex. Mol. Cell 24, 355–366 (2006). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16.Ewen ME et al. Functional interactions of the retinoblastoma protein with mammalian D-type cyclins. Cell 73, 487–497 (1993). [DOI] [PubMed] [Google Scholar]
- 17.Jahn SC et al. Assembly, activation, and substrate specificity of cyclin D1/Cdk2 complexes. Biochemistry 52, 3489–3501 (2013). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18.Chytil A et al. Construction of a cyclin D1–Cdk2 fusion protein to model the biological functions of cyclin D1–Cdk2 complexes. J. Biol. Chem. 279, 47688–47698 (2004). [DOI] [PubMed] [Google Scholar]
- 19.Jansen VM et al. Kinome-wide RNA interference screen reveals a role for PDK1 in acquired resistance to CDK4/6 inhibition in ER-positive breast cancer. Cancer Res. 77, 2488–2499 (2017). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20.Herrera-Abreu MT et al. Early adaptation and acquired resistance to CDK4/6 inhibition in estrogen receptor-positive breast cancer. Cancer Res. 76, 2301–2313 (2016). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21.James MK, Ray A, Leznova D & Blain SW Differential modification of p27Kip1 controls its cyclin D-cdk4 inhibitory activity. Mol. Cell. Biol. 28, 498–510 (2008). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22.Guiley KZ et al. p27 allosterically activates cyclin-dependent kinase 4 and antagonizes palbociclib inhibition. Science 366, eaaw2106 (2019). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23.Pagano M, Theodoras AM, Tam SW & Draetta GF Cyclin D1-mediated inhibition of repair and replicative DNA synthesis in human fibroblasts. Genes Dev. 8, 1627–1639 (1994). [DOI] [PubMed] [Google Scholar]
- 24.Chen SH et al. CRL4AMBRA1 targets elongin C for ubiquitination and degradation to modulate CRL5 signaling. EMBO J. 37, e97508 (2018). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 25.Xia P et al. WASH inhibits autophagy through suppression of beclin 1 ubiquitination. EMBO J. 32, 2685–2696 (2013). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26.Rogers ZN et al. Mapping the in vivo fitness landscape of lung adenocarcinoma tumor suppression in mice. Nat. Genet. 50, 483–486 (2018). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27.Simoneschi D & Pagano D CRL4AMBRA1 is a regulator of D-type cyclins. Nature (2021). [Google Scholar]
- 28.Maiani E, Milletti G, Bartek J & Cecconi F AMBRA1 regulates cyclin D to guard S-phase entry and genomic integrity. Nature (2021). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 29.Santra MK, Wajapeyee N & Green MR F-box protein FBXO31 mediates cyclin D1 degradation to induce G1 arrest after DNA damage. Nature 459, 722–725 (2009). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 30.Burkhart DL & Sage J Cellular mechanisms of tumour suppression by the retinoblastoma gene. Nat. Rev. Cancer 8, 671–682 (2008). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 31.Finn RS et al. PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro. Breast Cancer Res. 11, R77 (2009). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 32.Gong X et al. Genomic aberrations that activate D-type cyclins are associated with enhanced sensitivity to the CDK4 and CDK6 inhibitor abemaciclib. Cancer Cell 32, 761–776.e6 (2017). [DOI] [PubMed] [Google Scholar]
- 33.Finn RS et al. Biomarker analyses of response to cyclin-dependent kinase 4/6 inhibition and endocrine therapy in women with treatment-naive metastatic breast cancer. Clin. Cancer Res. 26, 110–121 (2020). [DOI] [PubMed] [Google Scholar]
- 34.DeMichele A et al. CDK 4/6 inhibitor palbociclib (PD0332991) in Rb+ advanced breast cancer: phase II activity, safety, and predictive biomarker assessment. Clin. Cancer Res. 21, 995–1001 (2015). [DOI] [PubMed] [Google Scholar]
- 35.Xue Y et al. CDK4/6 inhibitors target SMARCA4-determined cyclin D1 deficiency in hypercalcemic small cell carcinoma of the ovary. Nat. Commun. 10, 558 (2019). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 36.Liu J et al. An integrated TCA pan-cancer clinical data resource to drive high-quality survival outcome analytics. Cell 173, 400–416 (2018). [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Supplementary Materials
Data Availability Statement
Sequencing data from Tuba-seq experiments and RNA-sequencing data from AMBRA1-knockout U2OS cells are available from the Gene Expression Omnibus under accession numbers GSE146303 and GSE159920, respectively. Mass spectrometry data from shotgun proteomics experiments and analysis of ubiquitylated proteins are available through the ProteomeXchange Consortium, with dataset identifiers PXD021789 and PXD022111, respectively. Public nonprotected RNA-sequencing, copy number alteration, exome sequencing and reverse-phase protein array lung adenocarcinoma datasets from the TCGA were downloaded from https://gdc.cancer.gov/. Clinical data were obtained from a previous publication36 (PMID: 29625055). Gene dependency data from the Cancer Dependency Map are publicly available at www.depmap.org. Protein sequences for mass spectrometry analysis were obtained from the NCBI Homo sapiens protein database (ftp://ftp.ncbi.nlm.nih.gov/ref-seq/release/release-notes/archive/RefSeq-release86.txt, downloaded 05/11/2018) (shotgun mass spectrometry) and from Uniprot (https://www.uniprot.org/uniprot/?query=proteome:UP000005640%20reviewed:yes, downloaded 02/28/2020) (ubiquitin remnant profiling). All other data are available in the Article and supplementary information, or from the corresponding author upon reasonable request. Source data are provided with this paper.